Skip to main content

Table 1 Baseline patient demographics and clinical characteristics (treated set)

From: Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials

Values are mean (±SD) or % of subjects Linagliptin 5 mg (n = 366) Placebo (n = 146)
Age, years 59.8 (10.2) 58.8 (9.8)
Male, % 50.0 58.2
Race, %   
  American Indian/Alaska Native 0.5 0.7
  Asian 36.3 34.9
  Black/African American 1.6 1.4
  White 61.5 63.0
HbA1c, % 8.3 (0.9) 8.4 (0.9)
FPG, mg/dl* 176 (52) 178 (39)
BMI, kg/m2 29.9 (5.1) 29.9 (4.9)
eGFR, %   
  ≥ 90 ml/min 50.5 54.8
  60 to < 90 ml/min 41.5 38.4
  30 to < 60 ml/min 7.9 6.8
Urine albumin-to-creatinine ratio, mg/g, median (range) 60 (30–292) 64 (30–298)
SBP, mm Hg 138 (15) 135 (16)
DBP, mm Hg 81 (10) 81 (10)
Metabolic syndrome, % 64.8 60.3
Time since diagnosis of diabetes, %   
  Up to 1 year 11.2 13.7
  > 1 to 5 years 29.5 32.9
  > 5 years 59.3 53.4
Number of prior antidiabetes drugs, %   
  0 13.7 24.0
  1 35.5 31.5
  2 50.3 44.5
  3 0.5 0.0
Antihypertensive therapy, % 86.3 84.9
  Beta-blockers 29.8 23.3
  ACE inhibitors 40.4 41.1
  ARBs 21.0 19.9
  Diuretics 19.1 21.2
  Calcium antagonists 27.6 27.4
  Combinations 13.4 13.7
  1. *Linagliptin, n = 358; placebo, n = 144.
  2. Linagliptin, n = 348; placebo, n = 138.
  3. eGFR, estimated glomerular filtration rate, according to the Modification of Diet in Renal Disease study equation; ACE, angiotensin-converting enzyme; ARB, angiotensin-II receptor blocker.